Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioXcel Therapeutics (BTAI) Gross Profit (2022 - 2025)

BioXcel Therapeutics (BTAI) has 3 years of Gross Profit data on record, last reported at $87000.0 in Q3 2025.

  • For Q3 2025, Gross Profit rose 109.1% year-over-year to $87000.0; the TTM value through Sep 2025 reached -$212000.0, down 184.8%, while the annual FY2024 figure was $123000.0, 2.5% up from the prior year.
  • Gross Profit reached $87000.0 in Q3 2025 per BTAI's latest filing, up from $13000.0 in the prior quarter.
  • Across five years, Gross Profit topped out at $1.0 million in Q2 2024 and bottomed at -$956000.0 in Q3 2024.
  • Average Gross Profit over 3 years is $45000.0, with a median of $87000.0 recorded in 2025.
  • The widest YoY moves for Gross Profit: up 154.82% in 2024, down 459.06% in 2024.
  • A 3-year view of Gross Profit shows it stood at -$338000.0 in 2023, then crashed by 37.87% to -$466000.0 in 2024, then surged by 118.67% to $87000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Profit were $87000.0 in Q3 2025, $13000.0 in Q2 2025, and $154000.0 in Q1 2025.